Details of the Drug

General Information of Drug (ID: DMH0ZJE)

Drug Name

Mitomycin

Synonyms

Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Gastrointestinal cancer	2C11	Approved	[1]
Pancreatic adenocarcinoma	N.A.	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Urinary bladder cancer	N.A.	Approved	[2]
Urinary bladder neoplasm	N.A.	Approved	[2]
Urinary system neoplasm	N.A.	Approved	[2]
Urinary tract disease	GC2Z	Approved	[2]
Bladder disease	DC11-DC1Z	Investigative	[2]
Colon cancer	2B90.Z	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

334.33

Logarithm of the Partition Coefficient (xlogp)

-0.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is unstablely absorbed []
Half-life: The concentration or amount of drug in body reduced by one-half in 8 - 48 minutes [4]
Metabolism: The drug is metabolized via the hepatic []

Chemical Identifiers

Formula: C15H18N4O5
IUPAC Name: [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
Canonical SMILES: CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
InChI: InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
InChIKey: NWIBSHFKIJFRCO-WUDYKRTCSA-N

Cross-matching ID

PubChem CID: 5746
ChEBI ID: CHEBI:27504
CAS Number: 50-07-7
DrugBank ID: DB00305
TTD ID: D0Y0GH
VARIDT ID: DR01212
ACDINA ID: D01255

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Binder	[5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
A-kinase anchor protein 12 (AKAP12)	OTCVRDDX	AKA12_HUMAN	Drug Response	[7]
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Drug Response	[7]
Actin-binding LIM protein 1 (ABLIM1)	OTHXEK3E	ABLM1_HUMAN	Drug Response	[7]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1)	OTK71JYU	TCP4_HUMAN	Gene/Protein Processing	[8]
Acyl-coenzyme A thioesterase 2, mitochondrial (ACOT2)	OTAKUO27	ACOT2_HUMAN	Drug Response	[7]
Acylamino-acid-releasing enzyme (APEH)	OTX258QE	ACPH_HUMAN	Drug Response	[7]
Adhesion G-protein coupled receptor G1 (ADGRG1)	OTQBB8NT	AGRG1_HUMAN	Drug Response	[7]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Drug Response	[9]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Drug Response	[7]
Alternative prion protein (PRNP)	OTE85L1Q	APRIO_HUMAN	Gene/Protein Processing	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mitomycin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Roflumilast.	Asthma [CA23]	[10]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[11]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[11]
ABT-492	DMJFD2I	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[11]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Grepafloxacin	DMGLX0T	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Grepafloxacin.	Bronchitis [CA20]	[11]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Mitomycin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[12]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Mitomycin and Denosumab.	Low bone mass disorder [FB83]	[13]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Mitomycin and Thalidomide.	Multiple myeloma [2A83]	[14]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Tecfidera.	Multiple sclerosis [8A40]	[15]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Mitomycin and Siponimod.	Multiple sclerosis [8A40]	[16]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Mitomycin and Fingolimod.	Multiple sclerosis [8A40]	[17]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Ocrelizumab.	Multiple sclerosis [8A40]	[18]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Mitomycin and Ozanimod.	Multiple sclerosis [8A40]	[10]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[19]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[11]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Canakinumab.	Rheumatoid arthritis [FA20]	[20]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Rilonacept.	Rheumatoid arthritis [FA20]	[20]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Mitomycin and Golimumab.	Rheumatoid arthritis [FA20]	[21]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Mitomycin and Leflunomide.	Rheumatoid arthritis [FA20]	[12]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Mitomycin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[22]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Mitomycin due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[23]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Mitomycin and Azathioprine.	Transplant rejection [NE84]	[16]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[11]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[11]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Mitomycin due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[11]
Ganciclovir	DM1MBYQ	Moderate	Increased risk of nephrotoxicity by the combination of Mitomycin and Ganciclovir.	Virus infection [1A24-1D9Z]	[16]
Valganciclovir	DMS2IUH	Moderate	Increased risk of nephrotoxicity by the combination of Mitomycin and Valganciclovir.	Virus infection [1A24-1D9Z]	[16]
-----------


⏷ Show the Full List of 33 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Hypromellose	E00634	Not Available	Coating agent
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Water	E00035	962	Solvent
Hydroxyethyl-beta-cyclodextrin	E00631	Not Available	Other agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Mitomycin 40mg/vial powder	40mg/vial	Powder	Pyelocalyceal
Mitomycin 0.2mg/vial For solution	0.2mg/vial	For Solution	Topical
Mitomycin 5mg/vial injectable	5mg/vial	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
2	Mitomycin FDA Label
3	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.
6	In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
7	Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
8	Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ Health Perspect. 2003 May;111(6):825-35.
9	Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem. 2005 Jul 29;280(30):27998-8006. doi: 10.1074/jbc.M503698200. Epub 2005 May 19.
10	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
12	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
13	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
14	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
15	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
16	Cerner Multum, Inc. "Australian Product Information.".
17	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
18	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
19	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
20	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
21	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
22	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
23	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.